Previous 10 | Next 10 |
MALVERN, Pa., March 31, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company’s Chief Scientific ...
U.S. Food & Drug Administration (FDA) approves enrolling pediatric patients in the ongoing OCU400 Phase 1/2 trial who have: 1) RP associated with NR2E3 and RHO mutations and 2) LCA associated with CEP290 gene mutations Ocugen has completed enrollment of adult RP patients with NR2E...
MALVERN, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Sh...
2023-03-06 07:09:46 ET Ocugen ( NASDAQ: OCGN ) announced on Monday the appointment of Quan Vu as chief financial officer & chief business officer. Vu served as chief operating officer/chief business officer for 180 Life Sciences ( ATNF ) most recently. He joined Oc...
MALVERN, Pa., March 06, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced the appointment of Quan A. Vu to Chief Fina...
2023-03-04 10:00:00 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports a...
Ocugen ( NASDAQ: OCGN ) shares extended gains in the pre-market Wednesday after Chardan Capital Markets upgraded the COVID vaccine developer to Buy from Neutral, arguing that the company's recent selloff gives an attractive entry point ahead of multiple catalysts. After a rapid rise i...
Investors were pleased, if not overwhelmingly so, with Ocugen 's (NASDAQ: OCGN) latest set of quarterly results on Tuesday. The biotech published its fourth-quarter and full-year figures that morning, in addition to providing a business update. In reaction, the market bid up its stock by ...
Image source: The Motley Fool. Ocugen (NASDAQ: OCGN) Q4 2022 Earnings Call Feb 28, 2023 , 8:30 a.m. ET Operator Continue reading For further details see: Ocugen (OCGN) Q4 2022 Earnings Call Transcript
Ocugen, Inc. (OCGN) Q4 2022 Earnings Conference Call February 27, 2023 08:30 ET Company Participants Tiffany Hamilton - Head of Corporate Communications Shankar Musunuri - Chairman, Chief Executive Officer & Co-Founder Jessica Crespo - Chief Accounting Officer &...
News, Short Squeeze, Breakout and More Instantly...
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and va...
2024-07-11 08:45:00 ET It hasn't been a stellar year so far for biotech companies. The industry, as measured by the SPDR S&P Biotech ETF , is up just 4% since January, significantly lagging the S&P 500 's nearly 17% gain. Of course, it's not hard to find stocks that have...